Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
VTRS

VTRS - Viatris Inc Stock Price, Fair Value and News

11.64USD-0.20 (-1.69%)Delayed as of 22 Jul 2024, 01:55 pm ET

Market Summary

VTRS
USD11.64-0.20
Delayedas of 22 Jul 2024, 01:55 pm
-1.69%

VTRS Alerts

  • 1 major insider sales recently.

VTRS Stock Price

View Fullscreen

VTRS RSI Chart

VTRS Valuation

Market Cap

14.1B

Price/Earnings (Trailing)

-251.29

Price/Sales (Trailing)

0.92

EV/EBITDA

8.7

Price/Free Cashflow

6.83

VTRS Price/Sales (Trailing)

VTRS Profitability

EBT Margin

0.55%

Return on Equity

-0.28%

Return on Assets

-0.12%

Free Cashflow Yield

14.64%

VTRS Fundamentals

VTRS Revenue

Revenue (TTM)

15.4B

Rev. Growth (Yr)

-1.76%

Rev. Growth (Qtr)

-4.53%

VTRS Earnings

Earnings (TTM)

-56.1M

Earnings Growth (Yr)

-49.31%

Earnings Growth (Qtr)

114.88%

Breaking Down VTRS Revenue

52 Week Range

9.4611.76
(Low)(High)

Last 7 days

5.3%

Last 30 days

17.8%

Last 90 days

5.2%

Trailing 12 Months

13.1%

How does VTRS drawdown profile look like?

VTRS Financial Health

Current Ratio

1.67

Debt/Equity

0.8

Debt/Cashflow

0.15

VTRS Investor Care

Dividend Yield

4.06%

Dividend/Share (TTM)

0.48

Buy Backs (1Y)

0.70%

Diluted EPS (TTM)

-0.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202415.4B000
202315.8B15.6B15.5B15.4B
202217.6B17.2B16.7B16.3B
202113.8B15.6B17.2B17.9B
202011.6B11.7B11.8B11.9B
201900011.5B
201800011.4B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Viatris Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 14, 2024
malik rajiv
sold
-2,690,280
10.1789
-264,300
-
Jun 13, 2024
malik rajiv
sold
-900,741
10.5153
-85,660
-
May 28, 2024
roman brian
sold
-928,429
10.3829
-89,419
chief legal officer
Mar 13, 2024
mauro anthony
sold
-3,023,700
12.0948
-250,000
see remarks
Mar 05, 2024
lyons dillon joellen
sold
-247,200
12.36
-20,000
-
Mar 05, 2024
campbell paul
sold
-300,272
12.33
-24,353
see remarks
Mar 04, 2024
roman brian
sold (taxes)
-100,956
12.36
-8,168
global general counsel
Mar 04, 2024
ni xiangyang (sean)
acquired
-
-
8,222
president, greater china
Mar 04, 2024
campbell paul
acquired
-
-
19,427
see remarks
Mar 04, 2024
mauro anthony
acquired
-
-
39,784
see remarks

1–10 of 50

Which funds bought or sold VTRS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
Zhang Financial LLC
added
35.13
37,420
221,680
0.02%
Jul 19, 2024
RAYMOND JAMES & ASSOCIATES
reduced
-0.79
-1,864,290
14,101,100
0.01%
Jul 19, 2024
Hennion & Walsh Asset Management, Inc.
added
7.46
-103,091
2,276,180
0.12%
Jul 19, 2024
Sumitomo Mitsui Trust Holdings, Inc.
reduced
-9.37
-6,551,400
27,367,000
0.02%
Jul 19, 2024
TCW GROUP INC
sold off
-100
-206,407
-
-%
Jul 19, 2024
Continuum Advisory, LLC
unchanged
-
-134
2,426
-%
Jul 19, 2024
Raymond James Financial Services Advisors, Inc.
reduced
-2.22
-364,971
2,454,370
-%
Jul 19, 2024
China Universal Asset Management Co., Ltd.
reduced
-38.72
-1,238,570
1,487,000
0.21%
Jul 19, 2024
First Pacific Financial
new
-
5,975
5,975
-%
Jul 19, 2024
Venturi Wealth Management, LLC
new
-
8,590
8,590
-%

1–10 of 48

Are Funds Buying or Selling VTRS?

Are funds buying VTRS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VTRS
No. of Funds

Unveiling Viatris Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
11.86%
142,262,690
SC 13G/A
Feb 09, 2024
davis selected advisers
5.2%
62,661,728
SC 13G
Jan 30, 2024
state street corp
5.17%
61,969,119
SC 13G/A
Jan 26, 2024
blackrock inc.
7.7%
92,337,568
SC 13G/A
Feb 09, 2023
vanguard group inc
12.31%
149,318,666
SC 13G/A
Feb 07, 2023
state street corp
5.10%
61,903,672
SC 13G
Jan 31, 2023
blackrock inc.
7.7%
93,214,306
SC 13G/A
Feb 04, 2022
wellington management group llp
4.57%
55,233,099
SC 13G/A
Feb 03, 2022
blackrock inc.
7.2%
86,554,658
SC 13G/A
Feb 04, 2021
wellington management group llp
5.74%
69,811,210
SC 13G

Recent SEC filings of Viatris Inc

View All Filings
Date Filed Form Type Document
Jul 03, 2024
8-K
Current Report
Jun 17, 2024
4
Insider Trading
Jun 13, 2024
144
Notice of Insider Sale Intent
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
3
Insider Trading
Jun 03, 2024
8-K
Current Report
May 28, 2024
4
Insider Trading
May 28, 2024
144
Notice of Insider Sale Intent
May 09, 2024
8-K
Current Report
May 09, 2024
10-Q
Quarterly Report

Peers (Alternatives to Viatris Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
372.4B
85.6B
6.23% -8.11%
9.68
4.35
5.68% 202.39%
318.7B
61.4B
-1.70% 16.00%
138.18
5.19
6.11% -82.30%
177.7B
29.5B
8.27% 42.04%
47.23
6.02
12.76% -52.47%
169.7B
35.0B
9.27% -18.55%
146.05
4.84
-26.40% -92.03%
90.4B
27.4B
14.93% -9.21%
186.63
3.29
1.51% -91.32%
18.9B
16.0B
-1.18% 98.47%
-38.18
1.18
7.23% 71.10%
MID-CAP
4.2B
1.7B
1.72% -22.30%
9.67
2.43
54.01% 364.56%
3.8B
4.6B
9.59% -20.45%
-495.71
0.84
-0.06% 94.55%
2.8B
9.0B
17.62% -20.65%
-6.13
0.31
10.01% -27.45%
1.9B
676.2M
-1.12% -37.39%
12.52
2.86
30.38% 66.04%
SMALL-CAP
1.4B
743.2M
5.33% 7.88%
-3.91
1.85
24.65% 80.36%
21.2M
1.3M
-1.08% -55.56%
-2.86
16.12
-98.14% -104.71%
14.8M
89.6M
11.54% -18.69%
-1.04
0.19
287.27% -129.41%
9.8M
21.5M
320.59% -52.65%
-1.26
0.46
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Viatris Inc News

Latest updates
Seeking Alpha30 May 202407:00 am
Barchart24 May 202407:00 am
Yahoo Finance2 months ago

Viatris Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42018Q4
Revenue-4.5%3,6633,8373,9423,9193,7293,8764,0784,1174,1924,3424,5374,5784,4303,6242,9722,7312,619--
Gross Profit-5.8%1,5041,5971,6911,6091,5421,2741,7481,7031,7711,5461,5741,3281,1277061,1591,026906--
Operating Expenses-36.6%1,3002,0511,2401,2391,1421,4751,1881,1551,0641,6241,2171,3761,3941,588807892721--
  S&GA Expenses-36.6%1,0181,6061,0541,0329591,2651,0179819151,0831,0551,2051,1871,361658719605--
  R&D Expenses-200-211208183-175163142267152148184155130156114--
EBITDA Margin-4.3%0.22*0.23*0.39*0.39*0.39*0.40*0.28*0.28*0.27*0.25*0.23*--------
Interest Expenses-1.8%138141142144147147153146146148152167169144117116120--
Income Taxes201.5%91.00-89.4071.0069.0098.0045873.0075.0012860.00-11160.00596-97.7056.00-19.4010.00--
Earnings Before Taxes123.9%205-8554023333231,469428389528-203200-219-441-1,01324220.0031.00--
EBT Margin-58.0%0.01*0.01*0.16*0.16*0.17*0.17*0.07*0.05*0.02*-0.04*-0.09*--------
Net Income114.9%114-7653322642251,011354314399-263312-279-1,037-91518639.0021.00--
Net Income Margin-203.0%0.00*0.00*0.12*0.12*0.12*0.13*0.05*0.04*0.01*-0.07*-0.11*--------
Free Cashflow79.9%565314738447923-11.107657191,074326965--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Assets-0.7%47,34447,68648,74348,69549,29050,02248,66351,12553,46754,84356,07057,98458,97961,55311,41311,41231,256
  Current Assets-0.4%12,92412,97610,9329,7789,63010,63510,48811,17711,74410,90311,30811,75012,31912,86811,41311,4126,757
    Cash Equivalents2.3%1,0159921,3106295071,263647665752701757674807850665324491
  Inventory10.2%3,8233,4703,6723,6423,6643,5203,3803,6133,7973,9784,0824,4884,9425,472--2,671
  Net PPE-1.9%2,7082,7602,9272,9833,0083,0253,0393,0843,1503,1893,1143,1713,2473,460--2,150
  Goodwill-1.8%9,6949,86710,27810,53310,57310,42610,05510,52310,97912,11412,17011,99011,90712,347--9,591
Liabilities0.4%27,32927,21827,87727,85228,36228,95029,48031,32033,01934,35034,92936,77737,56538,59911,61411,41319,372
  Current Liabilities-0.2%7,7607,7776,8346,5246,1086,7466,5217,6819,6439,88410,10410,1339,97810,56379.0028.005,569
  Short Term Borrowings---0.0023.00205-5001,0206551,4931,7071,30137.001,101---
  Long Term Debt-0.7%16,07316,18817,07717,24618,06918,01518,72519,20618,76319,71719,85420,91722,10222,42911,53511,38511,214
    LT Debt, Current-2.3%1,8981,9431,3071,3345091,2597647682,6061,8781,9082,1842,3002,309--1,508
    LT Debt, Non Current-0.7%16,07316,18817,07717,24618,06918,01518,72519,20618,76319,71719,85420,91722,10222,42911,53511,38511,214
Shareholder's Equity-2.2%20,01420,46720,86620,84320,92821,07219,18219,80520,44820,49321,14121,20721,41522,95412,54811,74611,884
  Retained Earnings-0.7%4,6084,6405,5535,3695,2535,1764,3134,1073,9423,6894,0873,9104,3245,361-170-0.906,031
  Additional Paid-In Capital0.1%18,84018,81518,76118,71918,68018,64618,61718,58618,55518,53618,51418,49018,46518,439-31.00-0.308,644
Shares Outstanding-1,195---1,2031,2121,2121,2111,2111,2091,2091,2081,208----
Float----11,937---12,662---17,238-----
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations28.2%6154798345159711438698031,1395231,08655984936.00525380291----
  Share Based Compensation-16.3%47.0056.0043.0039.0043.0030.0029.0029.0028.0023.0025.0031.0033.0029.0015.0015.0019.00----
Cashflow From Investing-233.2%-154116-53.80-76.60-7491,785-115-82.10-66.90-219-118-16.80236-22.30-58.70-74.50-145----
Cashflow From Financing54.0%-425-926-97.60-303-974-1,330-758-779-1,009-349-877-685-1,099149-145-584-24.80----
  Dividend Payments-----------133----------
  Buy Backs-250---250----------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

VTRS Income Statement

2024-03-31
Condensed Consolidated Statements Of Operations - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Net sales$ 3,653.5$ 3,719.1
Total revenues3,663.43,729.1
Cost of sales2,159.42,186.9
Gross profit1,504.01,542.2
Operating expenses:  
Research and development199.7182.9
Selling, general and administrative1,017.5958.9
Litigation settlements and other contingencies, net76.80.6
Total operating expenses1,300.11,142.4
Earnings from operations203.9399.8
Interest expense138.4147.0
Other income, net(139.1)(69.9)
Earnings before income taxes204.6322.7
Income tax provision90.798.0
Net earnings$ 113.9$ 224.7
Earnings per share attributable to Viatris Inc. shareholders  
Basic (in USD per share)$ 0.10$ 0.19
Diluted (in USD per share)$ 0.09$ 0.19
Weighted average shares outstanding:  
Basic (in shares)1,195.21,202.5
Diluted (in shares)1,209.51,205.6
Other Research and Development Expense$ 6.1$ 0.0
Other Revenues  
Other revenues$ 9.9$ 10.0

VTRS Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 1,014.6$ 991.9
Accounts receivable, net3,632.03,700.4
Inventories3,823.23,469.7
Prepaid expenses and other current assets1,933.32,028.1
Assets held for sale2,520.42,786.0
Total current assets12,923.512,976.1
Property, plant and equipment, net2,708.22,759.6
Intangible assets, net19,133.719,181.1
Goodwill9,693.59,867.1
Deferred income tax benefit653.2692.9
Other assets2,231.62,208.7
Total assets47,343.747,685.5
Current liabilities:  
Accounts payable2,196.91,938.2
Income taxes payable148.4226.8
Current portion of long-term debt and other long-term obligations1,898.11,943.4
Liabilities held for sale234.8275.1
Other current liabilities3,281.73,393.9
Total current liabilities7,759.97,777.4
Long-term debt16,072.516,188.1
Deferred income tax liability1,671.91,735.7
Other long-term obligations1,825.11,516.9
Total liabilities27,329.427,218.1
Viatris Inc. shareholders’ equity  
Common stock: $0.01 par value, 3,000,000,000 shares authorized; shares issued: 1,230,891,074 and 1,221,994,491 as of March 31, 2024 and December 31, 202312.312.2
Additional paid-in capital18,839.818,814.7
Retained earnings4,607.54,639.7
Accumulated other comprehensive loss(2,941.0)(2,747.4)
Total Viatris Inc. equity, before treasury stock20,518.620,719.2
Less: Treasury stock — at cost504.3251.8
Total equity20,014.320,467.4
Total liabilities and equity$ 47,343.7$ 47,685.5
VTRS
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
 CEO
 WEBSITEviatris.com
 INDUSTRYPharmaceuticals
 EMPLOYEES38000

Viatris Inc Frequently Asked Questions


What is the ticker symbol for Viatris Inc? What does VTRS stand for in stocks?

VTRS is the stock ticker symbol of Viatris Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Viatris Inc (VTRS)?

As of Fri Jul 19 2024, market cap of Viatris Inc is 14.1 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VTRS stock?

You can check VTRS's fair value in chart for subscribers.

What is the fair value of VTRS stock?

You can check VTRS's fair value in chart for subscribers. The fair value of Viatris Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Viatris Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VTRS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Viatris Inc a good stock to buy?

The fair value guage provides a quick view whether VTRS is over valued or under valued. Whether Viatris Inc is cheap or expensive depends on the assumptions which impact Viatris Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VTRS.

What is Viatris Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, VTRS's PE ratio (Price to Earnings) is -251.29 and Price to Sales (PS) ratio is 0.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VTRS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Viatris Inc's stock?

In the past 10 years, Viatris Inc has provided -0.132 (multiply by 100 for percentage) rate of return.